5 Set-It-and-Forget-It Stocks to Buy in 2026

4. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders: 64

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 set-it-and-forget-it stocks to buy in 2026.

On March 19, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw its price target raised by Wells Fargo from $515 to $550. The firm’s analyst kept an Overweight rating on the shares. Wells Fargo anticipates a threefold growth in the market for the generalized Myasthenia Gravis (gMG), reaching $20 billion globally by 2036. Analysts cite new drugs and mechanisms, such as CD20, BAFF/APRILs, and next-generation complement inhibitors, as significant drivers of growth. The firm identifies Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Amgen (AMGN), and Regeneron (REGN) as the key beneficiaries of this growth, while expressing a notable belief in an upside to current Wall Street estimates.

In a separate event, on March 18, 2026, Maxim upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Buy and maintained a $575 price target. According to the firm, Povetacicept has the potential to be a blockbuster with “pipeline-in-a-product” capabilities. The analyst further noted that, alongside Journavx and Casgevy, the company has three products that provide crucial diversification beyond its cystic fibrosis franchise.

Founded in 1989, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. Based in Massachusetts, the company develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.